Karen•

“Los días sin ti son días conmigo” @elvirasastre ❤️‍🔥

Experts reach consensus to rename polycystic ovary syndrome (PCOS), better reflecting the condition’s full health impacts. Find out more 👉 spkl.io/6011ACDWW @ESEndocrinology #ECE2026

GLP-1s effectiveness at blood pressure control on par with traditional anti-hypertensives, tracks well with % weight loss

Obesity is masking heart failure — and we’re missing it ⚠️ #HF2026 PORTHOS study: largest population-based HF prevalence study in Southern Europe (n=6,189, 1 in 6 adults ≥50 has HF) Key finding: BMI shows a continuous inverse association with NT-proBNP — ~50 pg/mL less per 5 kg/m² increase Obese patients with LOW NT-proBNP (<125) vs lean patients above threshold: 🔴 More HF symptoms: OR 1.97 (p=0.013) 🔴 LA enlargement: OR 3.50 (p=0.010) 🔴 Echo abnormalities: OR 3.63 (p=0.016) Obese patients below the NP threshold carry GREATER HF burden than lean patients above it Marta Cobo Marcos, PORTHOS investigators #CardioTwitter #HFpEF #Obesity #NatriureticPeptides

#PRESS Our new data presented at the European Congress on Obesity highlights the powerful, consistent weight loss that our obesity injection delivers for women across all menopause stages. The data reveals that it also lowers risk of migraine, depression and cardiovascular disease, highlighting the broad support our medicine provides for women living with obesity. Learn more in the press release here: novonordisk.com/content/nncorp…

“Powerful framing from Milton Packer on obesity and HF: Adipose tissue isn’t just energy storage — it’s the body’s largest endocrine organ. Through adipokines, bioactive lipids, microRNAs, and inflammatory signaling, dysfunctional adipose tissue directly communicates with the myocardium, driving hypertrophy, fibrosis, and HF progression. Obesity-related HF is not simply a hemodynamic problem. It’s a systemic inflammatory and metabolic disease. 🫀 Understanding this biology is reshaping how we think about prevention and treatment in cardiometabolic disease. #HeartFailure #HFpEF #Obesity #CardioMetabolic #Cardiology #PreventiveCardiology #HeartFailure26

@Naynvrrt 🤠si me gustó open.spotify.com/album/2BiSmMZg…

“Another key concept from Milton Packer’s talk on obesity-related HFpEF: The target may not simply be weight loss — but reduction in visceral adiposity and correction of adipokine imbalance. Therapies including: • GLP-1 receptor agonists • SGLT2 inhibitors • MRAs • ARNI therapy • Bariatric surgery may improve HFpEF in part through favorable effects on visceral fat biology and inflammatory signaling. This reframes HFpEF as a cardiometabolic disease strongly linked to adipose tissue dysfunction, not just fluid overload or diastolic dysfunction alone. 🫀 #HFpEF #Obesity #CardioMetabolic #HeartFailure #GLP1 #SGLT2 #Cardiology” #HeartFailure26

Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials 👇 ow.ly/1WtE50YXchi #HeartFailure26 #HFA_ESC @HFA_President @Guio1212

Don't trust them.

No Doubt performing "Don't Speak" at the Sphere ✨️

Feliz #DiaDeLaMadre 💐 para todas las mamás humanas, que cuidan con amor y cariño a su perrito 🐾

👅

Fascinating slide from #HeartFailure26 🫀 People with CVD, hypertension & diabetes are at high risk of developing heart failure — and the comorbidity burden is staggering: • ~63% of HF patients have hypertension • ~56% have CAD or ischemic heart disease • ~50% have CKD • ~48% have hyperlipidemia • ~33% have diabetes Early intervention is key. Can we prevent HF before it starts? 🔬 #Cardiology #HeartFailure #Prevention #CVD #MedTwitter

System Of A Down “Aerials”